Evidence map›Paper›PMID 38374399›Full record

ArticleScientific reports2024

VAV2 orchestrates the interplay between regenerative proliferation and ribogenesis in both keratinocytes and oral squamous cell carcinoma.

Natalia Fernández-Parejo, L Francisco Lorenzo-Martín, Juana M García-Pedrero, Juan P Rodrigo, Mercedes Dosil, Xosé R Bustelo

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.3field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Natalia Fernández-Parejo *Centro de Investigación del Cáncer and Instituto de Biología Molecular del Cáncer, CSIC and Universidad de Salamanca, 37007, Salamanca, Spain.
L Francisco Lorenzo-Martín *Centro de Investigación del Cáncer and Instituto de Biología Molecular del Cáncer, CSIC and Universidad de Salamanca, 37007, Salamanca, Spain.
Juana M García-PedreroCentro de Investigación Biomédica en Red de Cáncer, 28029, Madrid, Spain.
Juan P RodrigoCentro de Investigación Biomédica en Red de Cáncer, 28029, Madrid, Spain.
Mercedes DosilCentro de Investigación del Cáncer and Instituto de Biología Molecular del Cáncer, CSIC and Universidad de Salamanca, 37007, Salamanca, Spain. mdosil@usal.es.
Xosé R BusteloCentro de Investigación del Cáncer and Instituto de Biología Molecular del Cáncer, CSIC and Universidad de Salamanca, 37007, Salamanca, Spain. xbustelo@usal.es.
Centro de Investigación Biomédica en Red de Cáncer · ESÉcole Polytechnique Fédérale de Lausanne · CHInstituto de Investigación Sanitaria del Principado de Asturias · ES

Funding

Worldwide Cancer Research 14-1248
6 · The paper itself

Abstract

VAV2 is an activator of RHO GTPases that promotes and maintains regenerative proliferation-like states in normal keratinocytes and oral squamous cell carcinoma (OSCC) cells. Here, we demonstrate that VAV2 also regulates ribosome biogenesis in those cells, a program associated with poor prognosis of human papilloma virus-negative (HPV

Indexed as

Carcinoma, Squamous CellHead and Neck NeoplasmsMouth NeoplasmsProto-Oncogene Proteins c-vavCell ProliferationHumansKeratinocytesrho GTP-Binding ProteinsRNA Polymerase ISquamous Cell Carcinoma of Head and NeckProto-Oncogene Proteins c-vavrho GTP-Binding ProteinsRNA Polymerase IVAV2 protein, humanGuanosine nucleotide exchange factorsOncogenic signalingPAK1Patient-derived cellsPatient prognosisRAC1RHOARHO GTPasesRibosomesRNA polymerase IROCKYAP/TAZ

Identifiers

PMID38374399
PMCPMC10876654
OpenAlexW4391945156

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.